- Home
- CB vs TGTX Comparison
CB vs TGTX Comparison
Compare CB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- TGTX
- Stock Information
- Founded
- CB 1985
- TGTX 1993
- Country
- CB Switzerland
- TGTX United States
- Employees
- CB N/A
- TGTX N/A
- Industry
- CB Property-Casualty Insurers
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- TGTX Health Care
- Exchange
- CB Nasdaq
- TGTX Nasdaq
- Market Cap
- CB 112.2B
- TGTX 4.2B
- IPO Year
- CB 1993
- TGTX 1995
- Fundamental
- Price
- CB $272.00
- TGTX $31.99
- Analyst Decision
- CB Buy
- TGTX Strong Buy
- Analyst Count
- CB 17
- TGTX 4
- Target Price
- CB $303.06
- TGTX $42.50
- AVG Volume (30 Days)
- CB 1.8M
- TGTX 2.0M
- Earning Date
- CB 10-28-2025
- TGTX 11-03-2025
- Dividend Yield
- CB 1.42%
- TGTX N/A
- EPS Growth
- CB N/A
- TGTX N/A
- EPS
- CB 22.66
- TGTX 0.36
- Revenue
- CB $57,486,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- CB N/A
- TGTX $82.58
- Revenue Next Year
- CB $5.67
- TGTX $44.99
- P/E Ratio
- CB $12.03
- TGTX $88.20
- Revenue Growth
- CB 7.11
- TGTX 30.96
- 52 Week Low
- CB $252.16
- TGTX $21.16
- 52 Week High
- CB $306.91
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- CB 43.21
- TGTX 56.18
- Support Level
- CB $274.53
- TGTX $31.34
- Resistance Level
- CB $283.31
- TGTX $32.56
- Average True Range (ATR)
- CB 3.56
- TGTX 1.12
- MACD
- CB -0.33
- TGTX 0.38
- Stochastic Oscillator
- CB 7.86
- TGTX 72.94
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.